LifeSciences BC > News > Member Announcements > Page 2

70% of Canadian Men’s Chronic Health Conditions are Caused by Lifestyle, not Genetics

June 11, 2018
Molecular You

Earlier detection of diabetes and cardiovascular issues with preventive action can reverse and prevent disease. UBC spin-off, Molecular You, offers a solution. Vancouver, BC – June 11, 2018 — Men’s Health Week, supported by the Canadian Men’s Health Foundation (CMHF), runs from June 11 to 17 this year. In support of Men’s Health, Molecular You, … Continue reading 70% of Canadian Men’s Chronic Health Conditions are Caused by Lifestyle, not Genetics

Zymeworks Closes Previously Announced Public Offering

June 11, 2018
Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today that it has closed its previously announced underwritten public offering (the “Offering”) of 6,210,000common shares, including the underwriters’ full exercise of their over-allotment option to purchase 810,000 additional shares,at a … Continue reading Zymeworks Closes Previously Announced Public Offering

MSFHR-Funded Researcher Discovers A New Drug That Could Stop Prostate Cancer In Its Tracks

June 8, 2018
Vancouver Prostate Centre

June 6, 2018 – Vancouver BC – Prostate cancer is the most common cancer among Canadian men – 1 in 7 will be diagnosed with the disease in their lifetime, and 1 in 29 will die from it.* 2007 Scholar & 2017 I2C award recipient Dr. Christopher Ong and fellow researchers at the Vancouver Prostate … Continue reading MSFHR-Funded Researcher Discovers A New Drug That Could Stop Prostate Cancer In Its Tracks

Xenon Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

June 2, 2018
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, June 01, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will present a corporate update at the Jefferies 2018 Healthcare Conference in New York on Wednesday, June 6, 2018 at 2:00 pm ET. A live audio webcast of the … Continue reading Xenon Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

Aequus Provides First Quarter 2018 Financial and Corporate Highlights

May 31, 2018
Aequus Pharmaceuticals Inc.

VANCOUVER, May 31, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the first quarter ended March 31, 2018 and associated Company developments. Unless otherwise noted, all figures are in Canadian currency. … Continue reading Aequus Provides First Quarter 2018 Financial and Corporate Highlights

Vancouver Medical Device Playbook 2018 draws 160 medtech company leaders from across North America

May 30, 2018
StarFish Medical

VICTORIA BC – May 28, 2018 – StarFish Medical announced that Vancouver Medical Device Playbook 2018 (#MDPLAYBOOK) drew an audience of 160 medtech company leaders, QA/Regulatory professionals, and R&D engineers from start-ups, manufacturers, consultancies, regulatory and academic organizations. 100% of attendee respondents to the post-event online survey rated the event as Excellent or Very Good. 95% … Continue reading Vancouver Medical Device Playbook 2018 draws 160 medtech company leaders from across North America

CDRD Builds Artificial Intelligence Capabilities Through New Partnership with Schrödinger Inc.

May 30, 2018
Centre for Drug Research and Discovery

CDRD, Canada’s national Centre for Drug Research and Development and Schrödinger Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, announced today that they have established a collaboration to use artificial intelligence (AI) to help facilitate the development of new therapeutic antibodies. Drug discovery and development is a long, expensive and … Continue reading CDRD Builds Artificial Intelligence Capabilities Through New Partnership with Schrödinger Inc.

BC Tech And Genome BC Team Up To Nurture Life Sciences Entrepreneurs

May 23, 2018

VANCOUVER, 22 May, 2018 – Today, HyperGrowth: Life celebrates the graduation of its second cohort — a group that promises to change the way we live, work and play with breakthroughs at the intersection of technology and the life sciences. Recognizing the tremendous potential that exists within the life sciences, in 2016 the BC Tech … Continue reading BC Tech And Genome BC Team Up To Nurture Life Sciences Entrepreneurs

DelMar Appoints Saiid Zarrabian to Full-Time President and CEO

May 22, 2018
Delmar Pharmaceuticals Inc

VANCOUVER, British Columbia and MENLO PARK, Calif., May 22, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (the “Company”)(NASDAQ: DMPI) today announced that the board of directors (the “Board”) has appointed Saiid Zarrabian as the full-time President and Chief Executive Officer of the Company, effective immediately. Mr. Zarrabian had previously served as the Company’s interim President and … Continue reading DelMar Appoints Saiid Zarrabian to Full-Time President and CEO

Global Health Sciences Fund invests 10 M USD in Canary Medical’s proprietary, “smart” implant technology designed to improve outcomes in post-surgical patients

May 18, 2018
Canary Medical Inc.

The Canary Health Implantable Reporting Processor (CHIRP) uses innovative sensor and novel communication technology in medical devices to enable remote patient monitoring. “Smart” medical devices will self-report on everything from patient activity to recovery and even treatment failure, without the need for physician intervention or a dependence upon patient compliance. Vancouver, British Columbia – May … Continue reading Global Health Sciences Fund invests 10 M USD in Canary Medical’s proprietary, “smart” implant technology designed to improve outcomes in post-surgical patients